ABM Therapeutics begins phase 1 trial of BRAF inhibitor ABM-1310

pharmanewsdaily- June 23, 2020

ABM Therapeutics said that the first cancer patient has been enrolled and dosed with its lead candidate ABM-1310, a BRAF inhibitor, in a phase 1 ... Read More

Differences between Malignant Tumors and Benign Tumors

pharmanewsdaily- November 24, 2013

What are the Characteristics of Neoplasia? Neoplasia comprises of both malignant and benign tumors. What are the differences between Malignant Tumors and Benign Tumors? Benign ... Read More